Characteristics | Median survival (95% CI) | Pa | Pb | ||
---|---|---|---|---|---|
Transthoracic | Thoracoabdominal | Transabdominal | |||
Sex | |||||
 Male | 5.66 (5.37–5.94) | 4.66 (4.27–5.05) | 3.84 (3.15–4.53) |  < 0.001* |  < 0.001 |
 Female | 5.69 (5.08–6.29) | 5.73 (3.53–7.94) | 4.79 (3.60–5.98) | 0.32 | |
Age (years) | |||||
  < 40 | 5.02 (1.93–8.12) | 3.29 (0.34–6.24) | Not reached | 0.34 |  < 0.001 |
 40–49 | 7.27 (5.23–9.31) | 7.27 (5.33–9.22) | 3.55 (1.98–5.12) | 0.10 | |
 50–59 | 7.04 (6.34–7.74) | 4.95 (4.19–5.71) | 6.268 (4.22–8.32) | 0.02 | |
 60–69 | 5.68 (5.31–6.04) | 4.73 (4.05–5.40) | 4.088 (3.33–4.84) | 0.002†| |
 70–79 | 4.00 (3.65–4.36) | 3.50 (2.19–4.82) | 2.70 (1.72–3.68) | 0.005‡ | |
  ≥ 80 | 3.51 (2.84–4.18) | 3.55 (1.49–5.61) | 1.22 (0.56–1.88) | 0.16 | |
Tumor stage | |||||
 0/I | 13.09 (8.90–17.27) | 9.39 (4.49–14.29) | Not reached | 0.60 |  < 0.001 |
 II | 7.70 (7.08–8.33) | 7.02 (5.26–8.78) | 6.95 (2.61–11.28) | 0.41 | |
 III | 4.23 (4.02–4.45) | 3.79 (3.31–4.27) | 3.16 (2.58–3.73) |  < 0.001 | |
 IV | 4.99 (3.60–6.38) | 3.09 (1.51–4.68) | 3.01 (1.53–4.50) | 0.03 | |
N stage | |||||
 N0 | 8.99 (8.23–9.75) | 8.51 (6.38–10.64) | 6.95 (2.67–11.22) | 0.31 |  < 0.001 |
 N1 | 4.46 (4.26–4.67) | 3.93 (3.55–4.31) | 3.16 (2.66–3.67) |  < 0.001 |